Maria Luisa Gasparri1,2, Giovanni Grandi3, Daniele Bolla2, Beat Gloor4, Sara Imboden2, Pierluigi Benedetti Panici1, Michael D Mueller2, Andrea Papadia5. 1. Department of Obstetrics and Gynecology, "Sapienza" University of Rome, Rome, Italy. 2. Department of Obstetrics and Gynecology, Inselspital, Berne University, Berne, Switzerland. 3. Department of Obstetrics and Gynecology, University of Modena, Modena, Italy. 4. Department of Surgery, Inselspital, Berne University, Berne, Switzerland. 5. Department of Obstetrics and Gynecology, Inselspital, Berne University, Berne, Switzerland. andrea.papadia@insel.ch.
Abstract
PURPOSE: Surgical cytoreduction remains a cornerstone in the management of patients with advanced and recurrent epithelial ovarian cancer. Parenchymal liver metastases determine stage VI disease and are commonly considered a major limit in the achievement of an optimal cytoreduction. The purpose of this manuscript was to discuss the rationale of liver resection and the morbidity related to this procedure in advanced and recurrent ovarian cancer. METHODS: A search of the National Library of Medicine's MEDLINE/PubMed database until March 2015 was performed using the keywords: "ovarian cancer," "hepatic," "liver," and "metastases." RESULTS: In patients with liver metastases, hepatic resection is associated with a similar prognosis as stage IIIC patients. The length of the disease-free interval between primary diagnosis and occurrence of liver metastases, as well as residual disease after resection, is the most important prognostic factors. In addition, the number of liver lesions, resection margins, and the gynecologic oncology group performance status seem to play also an important role in determining outcome. CONCLUSIONS: In properly selected patients, liver resections at the time of cytoreduction increase rates of optimal cytoreduction and improve survival in advanced-stage and recurrent ovarian cancer patients.
PURPOSE: Surgical cytoreduction remains a cornerstone in the management of patients with advanced and recurrent epithelial ovarian cancer. Parenchymal liver metastases determine stage VI disease and are commonly considered a major limit in the achievement of an optimal cytoreduction. The purpose of this manuscript was to discuss the rationale of liver resection and the morbidity related to this procedure in advanced and recurrent ovarian cancer. METHODS: A search of the National Library of Medicine's MEDLINE/PubMed database until March 2015 was performed using the keywords: "ovarian cancer," "hepatic," "liver," and "metastases." RESULTS: In patients with liver metastases, hepatic resection is associated with a similar prognosis as stage IIIC patients. The length of the disease-free interval between primary diagnosis and occurrence of liver metastases, as well as residual disease after resection, is the most important prognostic factors. In addition, the number of liver lesions, resection margins, and the gynecologic oncology group performance status seem to play also an important role in determining outcome. CONCLUSIONS: In properly selected patients, liver resections at the time of cytoreduction increase rates of optimal cytoreduction and improve survival in advanced-stage and recurrent ovarian cancerpatients.
Authors: G Veereman; J Robays; L Verleye; R Leroy; C Rolfo; E Van Cutsem; D Bielen; W Ceelen; E Danse; M De Man; P Demetter; P Flamen; A Hendlisz; I Sinapi; D Vanbeckevoort; D Ysebaert; M Peeters Journal: Crit Rev Oncol Hematol Date: 2015-01-14 Impact factor: 6.312
Authors: Valentin Kolev; Elena B Pereira; Myron Schwartz; Umut Sarpel; Sasan Roayaie; Daniel Labow; Mazdak Momeni; Linus Chuang; Peter Dottino; Jamal Rahaman; Konstantin Zakashansky Journal: Int J Gynecol Cancer Date: 2014-01 Impact factor: 3.437
Authors: Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer Journal: Cancer Date: 2009-03-15 Impact factor: 6.860
Authors: Melissa A Merideth; William A Cliby; Gary L Keeney; Timothy G Lesnick; David M Nagorney; Karl C Podratz Journal: Gynecol Oncol Date: 2003-04 Impact factor: 5.482
Authors: Andrea Papadia; Maria Luisa Gasparri; Alessandro Buda; Michael D Mueller Journal: J Cancer Res Clin Oncol Date: 2017-08-21 Impact factor: 4.553
Authors: Jorge Luna-Abanto; Luis García Ruiz; Jheff Laura Martinez; Manuel Álvarez Larraondo; Vladimir Villoslada Terrones Journal: J Gynecol Surg Date: 2020-03-31